ArticleCancer immunology, immunotherapy : CII2026
Fungal immunomodulatory proteins skew macrophages towards a pro-inflammatory and tumour inhibitory phenotype.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTumour-associated macrophages (TAMs) are associated with poor clinical outcome in cancer patients, making them key targets in immunotherapy. TAMs mainly consist of anti-inflammatory M2 macrophages promoting tumour growth, metastasis and immunosuppression. Fungal immunomodulatory protein from Nectria haematococca (FIP-nha) is a potential anti-tumour agent, notably inhibiting tumour cells and exerting immunomodulatory activity on macrophages. However, the anti-tumour activity of FIP-nha via TAMs modulation is still unclear. Here, the immunomodulatory activity of rFIP-nha on M1 and M2 macrophages was explored, as well as its anti-tumour activity via macrophage modulation, using M2 macrophages as TAM representatives, through an intricate co-culture design with A549 lung cancer cells.
methodsTHP-1-monocyte derived M2 macrophages were treated with rFIP-nha and analysed phenotypically. Subsequently, rFIP-nha treated M2 macrophages were co-cultured with A549 cells to investigate anti-tumour activity via macrophage modulation.
resultsrFIP-nha exposure decreased macrophages phagocytosis activity, enhanced IL-1β, IL-12 and IL-10 cytokine secretion, and modulated specific cell surface markers for M2 (CD163 and CD206) towards those that are typical for M1 (CD68 and CD80) polarization. rFIP-nha treated M2 macrophages polarized towards a tumour inhibitory phenotype which, when co-cultured with A549 cells, resulted in greater reduction of tumour cell proliferation compared to A549 cells co-cultured with M2 or M1 macrophages. Moreover, rFIP-nha exacerbated tumour inhibition and cell death.
conclusionrFIP-nha inhibited tumour growth in two distinct ways, by targeting tumour cells directly and by directing macrophage polarization towards a tumour inhibitory phenotype. This dual bioactivity makes FIP-nha interesting as an additive support in cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.